1
Country: USA | Funding: $272.5M
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
2
Country: UK | Funding: $50M
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
3
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
4
Country: USA | Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
5
Country: USA | Funding: $1.2B
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
6
Country: UK | Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
7
Country: USA | Funding: $447M
Pathos is a biotechnology company that leverages AI to accelerate solid tumor drug development.
Pathos is a biotechnology company that leverages AI to accelerate solid tumor drug development.
8
Country: USA | Funding: $331M
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
9
Country: USA | Funding: $220M
Soley Therapeutics has developed a platform that uses computer vision to capture the response of living cells to drug stress, transforming image characteristics into structured data and uses AI to distinguish drug activity from toxicity, identify mechanisms of action, identify pathways for new drug discovery. Computer vision recognizes features invisible to the human eye that result from a variety of intracellular events, such as protein movement, localization, expression and organelle and membrane dynamics. The company's automated infrastructure enables the screening of over 100,000 compounds per week. The company's first drugs have demonstrated high preclinical efficacy in both hematological and solid tumors. They are also being tested for the treatment of neurodegenerative diseases, obesity/metabolic diseases and hair regeneration.
Soley Therapeutics has developed a platform that uses computer vision to capture the response of living cells to drug stress, transforming image characteristics into structured data and uses AI to distinguish drug activity from toxicity, identify mechanisms of action, identify pathways for new drug discovery. Computer vision recognizes features invisible to the human eye that result from a variety of intracellular events, such as protein movement, localization, expression and organelle and membrane dynamics. The company's automated infrastructure enables the screening of over 100,000 compounds per week. The company's first drugs have demonstrated high preclinical efficacy in both hematological and solid tumors. They are also being tested for the treatment of neurodegenerative diseases, obesity/metabolic diseases and hair regeneration.
10
Country: USA | Funding: $216M
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
Dispatch Bio was formed around the concept of solving two obstacles in cancer care: developing a treatment that can differentiate cancer cells from healthy cells while also addressing resistance mechanisms.
11
Country: UK | Funding: $188M
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
12
Country: USA | Funding: $15.7M
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
